We thank Liakakos and colleagues for their thoughtful comments regarding our article and agree that our study is limited by its retrospective design and the absence of a uniform protocol and treatment approach. We have certainly noted these limitations in our manuscript.1 Liakakos et al. have outlined a genomic-based model for treatment of gastric cancer and they do an excellent job of proposing some of the potential benefits and challenges of this approach. We would also like to thank Ziogas and colleagues for their comments regarding another recent article describing the outcomes of attempted surgery for recurrent gastroesophageal cancer.2 Our colleagues are reasonable in pointing out the relatively small and select population of this study and the limitations inherent to the retrospective analysis. Similarly to Liakakos, they highlight the need for individualized adjuvant treatment and we share in the hope that gene-expression profiling may allow for improved treatment options.